• 1
    Bytzer P., Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol 2002; 97: 60411.
    Direct Link:
  • 2
    Russo A, Fraser R, Adachi K, Horowitz M, Boeckxstaens G. Evidence that nitric oxide mechanisms regulate small intestinal motility in humans. Gut 1999; 44: 726.
  • 3
    Gangula PR, Maner WL, Micci MA, Garfield RE, Pasricha PJ. Diabetes induces sex-dependent changes in neuronal nitric oxide synthase dimerization and function in the rat gastric antrum. Am J Physiol Gastrointest Liver Physiol 2007; 292: 72533.
  • 4
    Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15 000 adults. Arch Intern Med 2001; 161: 198996.
  • 5
    Nakao K, Takahashi T, Utsunomiya J, Owyang C. Extrinsic neural control of nitric oxide synthase expression in the myenteric plexus of rat jejunum. J Physiol 1998; 507: 54960.
  • 6
    Martinez-Cuesta MA, Massuda H, Whittle BJ, Moncada S. Impairment of nitrergic-mediated relaxation of rat isolated duodenum by experimental diabetes. Br J Pharmacol 1995; 114: 91924.
  • 7
    Watkins CC, Sawa A, Jaffrey S et al. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest 2000; 106: 37384.
  • 8
    He CL, Soffer EE, Ferris CD, Walsh RM, Szurszewski JH, Farrugia G. Loss of interstitial cells of cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology 2001; 121: 42734.
  • 9
    Von Der Ohe MR. Diarrhoea in patients with diabetes mellitus. Eur J Gastroenterol Hepatol 1995; 7: 7306.
  • 10
    Valdovinos MA, Camilleri M, Zimmerman BR. Chronic diarrhea in diabetes mellitus: mechanisms and an approach to diagnosis and treatment. Mayo Clin Proc 1993; 68: 691702.
  • 11
    Ogbonnaya KI, Arem R. Diabetic diarrhea. Pathophysiology, diagnosis, and management. Arch Intern Med 1991; 150: 2627.
  • 12
    Morbini P, Villa C, Campo I, Zorzetto M, Inqhilleris S, Luisetti M. The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Mod Pathol 2006; 19: 143745.
  • 13
    Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs 2006; 7: 98591.
  • 14
    Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 12946.
  • 15
    Korenaga K, Micci MA, Taglialatela G, Pasricha PJ. Suppression of nNOS expression in rat enteric neurons by the receptor for advanced glycation end-products. Neurogastroenterol Motil 2006; 18: 392400.
  • 16
    Cameron NE, Cotter MA, Dines K, Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1992; 35: 94650.
  • 17
    Liu J, Qiao X, Micci MA, Pasricha PJ, Chen JD. Improvement of gastric motility with gastric electrical stimulation in STZ-induced diabetic rats. Digestion 2004; 70: 15966.
  • 18
    Twigg SM, Cao Z, MCLennan SV et al. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 2002; 143: 490715.
  • 19
    Cellek S, Qu W, Schmidt AM, Moncada S. Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: a new insight into selective nitrergic neuropathy in diabetes. Diabetologia 2004; 47: 3319.
  • 20
    Bierhaus A, Schiekofer S, Schwaninger M et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50: 2792808.
  • 21
    Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE- induced collagen production in NRK-49 F cells. J Cell Biochem 2001; 81: 10213.
  • 22
    Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21 (ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997; 272: 178104.
  • 23
    Li JH, Wang W, Huang XR et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol 2004; 164: 138997.
  • 24
    Usta MF, Bivalacqua TJ, Yang DY et al. The protective effect of aminoguanidine on erectile function in streptozotocin diabetic rats. J Urol 2003; 170: 143742.
  • 25
    Xu B, Chibber R, Ruggiero D, Kohner E, Ritter J, Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003; 17: 128991.
  • 26
    Usta MF, Kendirci M, Gur S et al. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. J Sex Med 2006; 3: 24250.
  • 27
    Matsunaga N, Anan I, Forsgren S et al. Advanced glycation end products (AGE) and the receptor for AGE are present in gastrointestinal tract of familial amyloidotic polyneuropathy patients but do not induce NF-kappaB activation. Acta Neuropathol 2002; 104: 4417.
  • 28
    Cellek S, Foxwell NA, Moncada S. Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2003; 52: 235362.
  • 29
    Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003; 419: 3140.
  • 30
    Thornalley PJ, Yurek-George A, Argirov OK. Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem Pharmacol 2000; 60: 5565.
  • 31
    Giardino I, Fard AK, Hatchell DL, Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 1998; 47: 111420.
  • 32
    Mustafa A, Gado AM, Al-Shabanah OA, Al-Bekairi AM. Protective effect of aminoguanidine against paraquat-induced oxidative stress in the lung of mice. Comp Biochem Physiol C Toxicol Pharmacol 2002; 132: 3917.
  • 33
    Kumari K, Umar S, Bansal V, Sahib MK. Monoaminoguanidine inhibits aldose reductase. Biochem Pharmacol 1991; 41: 15278.
  • 34
    Price DL, Rhett PM, Thorpe SR, Baynes JW. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001; 276: 4896772.
  • 35
    Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357: 593615.
  • 36
    Jianmongkol S, Vuletich JL, Bender AT, Demady DR, Osawa Y. Aminoguanidine-mediated inactivation and alteration of neuronal nitric-oxide synthase. J Biol Chem 2000; 275: 133706.
  • 37
    Vasan S, Zhang X, Zhang X et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996; 382: 2758.
  • 38
    Cooper ME, Thallas V, Forbes J et al. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 2000; 43: 6604.
  • 39
    Roufail E, Soulis T, Boel E, Cooper ME, Rees S. Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine. Diabetologia 1998; 41: 141925.
  • 40
    Shotton HR, Adams A, Lincoln J. Effect of aminoguanidine treatment on diabetes-induced changes in the myenteric plexus of rat ileum. Auton Neurosci 2007; 132:1626.
  • 41
    Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002; 1: 115.